Trials / Completed
CompletedNCT01373619
Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- University of Campania Luigi Vanvitelli · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Heart failure with normal ejection fraction is often under diagnosed and certainly under treated in hemodialyzed patients. Because of the benefit of reducing heart rate, ivabradine, a pure heart-rate lowering agent without effects on blood pressure, is of potential therapeutic utility.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivabradine | ivabradine titrated to 7.5 mg BID |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2011-01-01
- Completion
- 2012-01-01
- First posted
- 2011-06-15
- Last updated
- 2012-01-19
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT01373619. Inclusion in this directory is not an endorsement.